H.C. Wainwright analyst Sara Nik reiterated a Buy rating on Curis (CRIS – Research Report) today and set a price target of $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sara Nik’s rating is based on the promising potential of Curis’s novel IRAK4 inhibitor, emavusertib, particularly in treating relapsed/refractory primary central nervous system lymphoma (r/r PCNSL). Recent data presented by Curis at ASCO 2025 highlighted the significant pharmacokinetic properties of emavusertib, showing a dose-dependent increase in cerebrospinal fluid and plasma concentrations, which is crucial for its efficacy.
Furthermore, the targeted sequencing of patients in the study revealed a distinct mutational profile among responders, with mutations in genes such as TP53, GALNT12, WT1, and BMPR1A. These findings not only enhance the understanding of emavusertib’s clinical activity but also suggest its broader potential in treating lymphoma patients. Such encouraging results underpin the Buy rating, reflecting confidence in the drug’s future impact and the company’s strategic direction.